Large-scale testing (Phase 3)UnknownNCT01352091What this trial is testingAdjuvant AI Combined With ZoladexWho this might be right forBreast Cancer Fudan University 670
Large-scale testing (Phase 3)Ended earlyNCT06038539What this trial is testingEfficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast CancerWho this might be right forHR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Biocon Biologics UK Ltd 55
Very early researchWithdrawnNCT04088032What this trial is testingNeoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast CancerWho this might be right forBreast Cancer FemaleLocally Advanced Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast Alison Stopeck
Not applicableLooking for participantsNCT06534125What this trial is testingAcutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast CancerWho this might be right forAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more Emory University 150
Early research (Phase 1)Study completedNCT01576666What this trial is testingPhase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid TumorsWho this might be right forDose EscalationSafetyPreliminary Efficacy+9 more Novartis Pharmaceuticals 120
Large-scale testing (Phase 3)Ended earlyNCT00908531What this trial is testingTrial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast CancerWho this might be right forOperable Breast Neoplasms Danish Breast Cancer Cooperative Group 123
Testing effectiveness (Phase 2)Looking for participantsNCT06517212What this trial is testingTirzepatide Weight Loss for MRD+ Early Breast CancerWho this might be right forBreast CancerBreast NeoplasmsBreast Cancers Baylor Research Institute 48
Testing effectiveness (Phase 2)Active Not RecruitingNCT05165225What this trial is testingPhase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label TrialWho this might be right forBreast CancerHER2-low-expressing Breast CancerHormone Receptor-positive Breast Cancer+1 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 48
Not applicableStudy completedNCT01446185What this trial is testingTreatment Decision Impact of OncotypeDX™ in HR+, N- Breast Cancer PatientsWho this might be right forBreast Cancer Genomic Health®, Inc. 100
Testing effectiveness (Phase 2)Looking for participantsNCT01042379What this trial is testingI-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerWho this might be right forBreast NeoplasmsBreast CancerBreast Tumors+8 more QuantumLeap Healthcare Collaborative 5,000
Large-scale testing (Phase 3)Looking for participantsNCT05760612What this trial is testingAdjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus PertuzumabWho this might be right forEarly-stage Breast CancerHER2-positive Breast CancerAdjuvant Treatment After Trastuzumab+2 more Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 300
Large-scale testing (Phase 3)Study completedNCT00309478What this trial is testingRandomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive PatientsWho this might be right forEarly-stage Breast Cancer Austrian Breast & Colorectal Cancer Study Group 1,099
Testing effectiveness (Phase 2)Looking for participantsNCT06970912What this trial is testingCtDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast CancerWho this might be right forHormone Receptor-Positive Breast CancerHigh-risk Breast CancerEarly-Stage Breast Cancer+3 more Peking University People's Hospital 393
Large-scale testing (Phase 3)WithdrawnNCT03081234What this trial is testingAdjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWho this might be right forBreast Cancer Novartis Pharmaceuticals
Not applicableActive Not RecruitingNCT03904173What this trial is testingEstablishment of Molecular Profiling for Individual Clinical Routine Treatment Decision in Early Breast CancerWho this might be right forBreast CancerBreast NeoplasmsHormone Receptor Positive Tumor Oslo University Hospital 2,300
Not applicableLooking for participantsNCT06106477What this trial is testingImpact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast CancerWho this might be right forBreast Cancer Medical College of Wisconsin 20
Not applicableEnded earlyNCT01121549What this trial is testingA Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast CancerWho this might be right forInvasive Early Breast Cancer Pfizer 378
Not applicableLooking for participantsNCT06050109What this trial is testingThe Benefits of Continued Use of Ovarian Function Suppression After 5 YearsWho this might be right forBreast Cancer FemaleEndocrine Therapy Hongmei Zheng, PhD 1,200
Testing effectiveness (Phase 2)Looking for participantsNCT04553770What this trial is testingTrastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerWho this might be right forEarly-stage Breast CancerHormone Receptor Positive Breast CarcinomaInvasive Breast Cancer+4 more Jonsson Comprehensive Cancer Center 88
Testing effectiveness (Phase 2)Active Not RecruitingNCT05252988What this trial is testingThree Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibWho this might be right forEarly-stage Breast CancerHER2 Positive Breast CancerHormone Receptor Positive Spanish Breast Cancer Research Group 177